CORAR Leadership
CORAR Executive Director
Michael J. Guastella, MS, MBA - Executive Director
Before joining CORAR in 2011, Michael held various sales and marketing leadership roles in the imaging, biotechnology, clinical laboratory, and radiopharmaceutical industries and was most recently the Vice President of Marketing and Product Development for Cardinal Health Nuclear Pharmacy Services. Michael has served on the CORAR Board of Directors for 10 years and has held other industry leadership positions including Co-Chairman of the CORAR Healthcare Policy Committee – Reimbursement. Michael received his B.S. and M.S. degrees from UCLA and earned his MBA from the UCLA Anderson School of Management.
2024 CORAR Corporate Officers
Chairman
John Wiggins - Vice President Isotope Strategy, Lantheus
Vice Chairman
David Pellicciarini - Vice President, Quality and Regulatory, Cardinal Health Nuclear & Precision Health Solutions
Secretary/Treasurer
James T. Harvey - Senior Vice President & Chief Science Officer, NorthStar Medical Radioisotopes, LLC
2024 CORAR Board Members
Shahe Bagerdjian (International Isotopes, Inc.)
Roy Brown (Curium)
Jonathan Cirtain (BWXT Medical)
Scott Claunch (TerraPower Isotopes)
James Cook (Evergreen Theragnostics, Inc)
Roger Estafanos (ITM USA, Inc.)
Shaemus Gleason (Clarity Radiopharmaceuticals)
James T. Harvey (NorthStar Medical Radioisotopes, LLC)
Rohan Jain (Nusano, Inc.)
Campbelle Mongilia (Sun Radiopharma)
Wayne Mullet (Boston Scientific)
Michael Pintek (Cardinal Health)
Matt Sanford (University of Missouri Research Reactor)
Eric Schutt (SHINE Medical Technologies)
Jay Simon (Eckert & Ziegler Radiopharma)
Geoff Towle (Advanced Accelerator Application, a Novartis Company)
Chris Wagner (Eden Radioisotopes, LLC)
John Wiggins (Lantheus Holdings, Inc.)
Jim Wilson (Eckert & Ziegler Isotope Products)
Latest News
-
MITA and CORAR Support House Bill to Foster Access to Innovative Medical Imaging https://t.co/Riwxdv6noS #CORAR
-
CORAR Comments on FDA Draft 503B RP Compounding Guidance https://t.co/EJMpjHYcz4 #CORAR
-
CORAR Comments on FDA Draft Nuclear Pharmacy Compounding Guidance https://t.co/Hhcem9KabR #CORAR